Articles About Medtech

This Life-Saving Breakthrough Is Saving COVID Patient’s Hearts and Giving You The Opportunity To Take Advantage Of A Projected $600 Billion Industry

0 | By Michael A. Robinson

Devan Smith had one foot in the grave.

After contracting COVID-19 last May, he was hospitalized with severe respiratory issues and multiorgan failure.

And if that wasn’t bad enough, the 42-year Pennsylvania warehouse worker also had to deal with a malfunctioning heart. That alone could have killed him.

But doctors at the Mercy Catholic Medical Center in Pennsylvania were able to save Smith in no small measure because of a tiny heart pump.

Known as the Impella, that device received an emergency use authorization from the FDA to treat coronavirus patients only weeks before.

Of course, Smith credits the medical team with saving his life. But he’s quick to point out that the Impella played a big role in it all.

And Bill is not alone.

These kinds of heart complications are reported to affect as many as 10% of COVID-19 patients.

Fortunately for tech investors, there’s a lot more going on here than a feel-good feature story.

The medical device market is worth $625 billion, and the company behind Impella can grab a big chunk of that.

And make you a lot of money…

There’s a “Silent Partner” In the Project for A Post-COVID America – And You Can Buy It At A Great Discount

1 | By Michael A. Robinson

The best minds in biotech are working round the clock on putting a stop to the COVID-19 pandemic. The project includes over 135 vaccine candidates and the profit potential here is massive.

This is literally about saving the world.

The thing is, though, vaccines are only one part of this project. There’s another dimension, a “silent partner” in the project that doesn’t get quite so much heroic headline ink but is just as important.

You see, of all the vaccines coming down the pipeline, 31 are currently in human trials. There’s a very good chance that one of them will be safe and powerful enough to begin mass distribution in early 2021.

But there are 328 million living Americans and 7.5 billion humans on planet earth. It will take time to vaccinate them all, and that’s where our “silent partner” comes in.

It’s blazing a trail towards the kind of better COVID-19 testing technology we will need to get things fully back to normal.

And not only that, it’s on a solid track to double your money in just two years…

The Doctor’s Office Visit Is History, and What Comes Next Could Make You A Fortune

1 | By Michael A. Robinson

Looking for a parking spot for 15 minutes, spending 20 minutes filling out forms, and waiting for 30 minutes or more to see your doctor is a relic of the past thanks to virtual medical appointments through our computers and phones.

And it’s easy to see why.

What’s referred to as “telemedicine” can save patients nearly two hours of their time, according to Forbes.

Being in the comfort of their own homes is also a major selling point, as a Doctor.com survey found that 91% of the respondents said telemedicine would:

  • Help them stick to their appointments.
  • Manage prescriptions and refills.
  • Follow wellness regimens suggested by their doctor.

Keep in mind folks that telemedicine was becoming more commonplace, and then COVID-19 sent it into overdrive.

As far as hard numbers go, telemedicine forecasts B.C. (before coronavirus) show this market is only getting more valuable, climbing 127% from $35.5 billion dollars to $80.6 billion by 2025.

So those estimates could be too conservative, and I don’t want you to wait around to make money as this market gets bigger and bigger.

The good news is there’s a fire sale going on in the telemedicine market that we can take advantage of right now that will pave your road to wealth.

I’m talking about Teledoc Health Inc. (TDOC), which got slammed on August 5, closing down 19%.

The reason was that the firm is making a big buyout, one that I think is very savvy.

If everyone else takes that as a sign to sell, all the better for us…

A “Super Vaccine” Deal Has Gone into Overdrive After This Latest News

1 | By Michael A. Robinson

The COVID-19 pandemic is and has been an unprecedented event, but there’s also something else to think about.

During this moment in history, we have never had a unified global effort quite like this to find an effective vaccine, and the convergence of technology and medicine that we have access to is allowing researchers to work on a vaccine at break-neck speed.

As of this writing, there are currently 28 COVID-19 vaccines in human trials, and the Trump Administration believes it will have an effective vaccine by 2021.

To get there, the federal government is spending an unprecedented $10 billion

The “Super Vaccine” and Your 10X Profit Potential Within the Next Year

0 | By Strategic Tech Investor Staff

From scientists to business leaders, there’s one thing most people can agree on – life will not return to normal and our economy will not reach maximum production until a vaccine for COVID-19 is in hand. To find this vaccine, the convergence between tech and medicine is creating a biotechnology revolution.

Operation Warp Speed (OWS), an initiative in the United States, aims to deliver over 300 million doses of a safe, effective vaccine for COVID-19 by January 19, 2021.

And as of this writing, what we call a new, viable “Super Vaccine” is pushing to begin production of up to one billion doses. Right now, a tiny company behind the Super-Vaccine has a mere $60 million a year in sales.

But with production expected to begin imminently, it could create a staggering 58,300% revenue surge by year’s end

Wall Street Counted This Dental Tech Innovator Out – Here are Five Reasons Why You Should Buy Them Anyways

1 | By Michael A. Robinson

We’re coming up on the one-year anniversary of what at the time seemed like a controversial call.

But it turned out to be very profitable.

See, back on July 26, 2019, I suggested you invest in a breakout stock that had just gotten slaughtered.

My column appeared the very day after the company I have in mind lost more than 25% of its value – in a single session.

Despite that drubbing, I struck a very confident tone. How could I be so sure of a strong return?

Fair question. Simple answer. The company has a long track record of excellent earnings growth.

And those kinds of stocks very often not only weather setbacks but go on to become market leaders once again. This medical device leader rallied back by 40% in just five months.

Today, I want to show you five reasons why in just 10 weeks this stock had peak gains during the coronavirus comeback of 104%

One In Five Americans Could Need This Company’s Services By 2030 – And They Can Claim You A Piece Of $225 Billion

1 | By Michael A. Robinson

The easiest class I took in college more than 40 years ago is turning out to be very valuable these days.

It was a sociology course on aging that I rarely attended. But I did read the textbook carefully,

And I’m glad I did. It helped prepare for recent events involving my in-laws and my dad.

We recently had to move my aging in-laws into an assisted living facility. Meanwhile my dad, age 87, wants to remain at home but needs regular care.

I’m bringing this all up because it’s part of a huge national trend. By 2030, 20% of the population will be seniors, nearly double the figure in 2009.

By 2024, this demographic will push the home healthcare market to $225 billion, up 125% from the 2016 level.

And today, I’m going to reveal a leader in this field whose stock could double in less than two years

The Race for A COVID-19 Vaccine Is Speeding Up

1 | By Alex Kagin

July 4 is one of my favorite holidays, and living in D.C., the excitement is intensified as a huge parade marches through the city and the night concludes at the National Mall with fireworks.

But this year will be very different.

Fireworks in the nation’s capital will take place in some form with many people watching from home and the National Independence Day Parade has been cancelled. The rest of the country is also still affected by COVID-19.

Eli Lilly and Johnson & Johnson Tackle COVID-19

2 | By Alex Kagin

Living in Washington, D.C., it’s good to see that COVID-19 cases, which peaked on April 30, continue to decline. As a result, restaurants, retail stores, and some barbershops have started to open in a limited capacity.

But that reopening isn’t happening everywhere.

There are still thousands of new cases daily across the United States and many states that have started to open back up such as Texas, California, and Florida continue to see a rise in new COVID-19 cases.

Five Reasons Why This Pharmaceutical Specialist Could Double Your Money in Just Two Years

0 | By Michael A. Robinson

In our twice-weekly chats, I often suggest investments that are part of large tech sectors.

For instance, the life sciences field defines huge. Just the prescription drug segment alone will be worth $1.2 trillion by 2024, according to data from Statista.

So, you might be wondering why I am focused on a medical area that will be worth just 0.1% of that figure over roughly the same time frame.

It’s a fair question. The answer is pretty basic. A high-octane leader
focused on specialty drugs can make a killing.

And the one I’m going to reveal to you today defines profit machine. It’s on pace to double per-share earnings in as little as a year.

With that in mind, let me show you five reasons why this wealth-building biotech firm should at the very least be on your radar screen….